BRIEF TITLE * (in English and Sufficiently Descriptive) Role of MRI in Anti-LGI1 Encephalitis

CompletedOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

June 20, 2022

Primary Completion Date

September 20, 2022

Study Completion Date

December 20, 2022

Conditions
Autoimmune Encephalitis
Interventions
OTHER

Retrospective evaluation of specific brain MRI features

"Initial brain MRI and subsequent follow-up studies will be reviewed to document the presence of specific MRI features, and their association with greater disease severity in the acute phase and/or neurological sequelae after encephalitis resolution will be investigated. More specifically, we will analyze the presence of:~* Brain MRI changes in the acute stage, i.e. \< 3 months from symptoms onset, including abnormal signal intensity, altered diffusion and/or contrast enhancement in the hippocampus (unilateral/bilateral), abnormal signal intensity in basal ganglia, insula, and/or perisylvian cortex, presence of global brain atrophy, presence of hippocampal atrophy and/or MTS, hippocampal volumetry~* Brain MRI changes after acute phase resolution (\> 6 months after symptoms onset) including abnormal signal intensity in the hippocampus (unilateral/bilateral), presence of global brain atrophy, presence of hippocampal atrophy and/or MTS, hippocampal volumetry"

Trial Locations (1)

69677

Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites autoimmunes, Lyon

All Listed Sponsors
lead

Hospices Civils de Lyon

OTHER